Mounjaro

Mounjaro is the original tirzepatide brand — Eli Lilly’s first dual GLP-1/GIP agonist, FDA-approved for type 2 diabetes in 2022. The weight loss seen in SURPASS trials was so significant that Lilly spun off a second brand (Zepbound) specifically for obesity. Mounjaro stays the diabetes brand. Our coverage includes Mounjaro cost without insurance, dosing escalation, and why pricing differs from Zepbound despite being the same drug.